Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Alcohol Misuse, Cannabis Misuse
Interventions: Brief Negotiation Interview intervention (BNI) (adapted); Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Coronary Artery Disease
Interventions: Technetium Tc99m Tetrofosmin injections, Thallous Chloride T1-201; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Breast Cancer
Interventions: Fulvestrant, Ganetespib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: Weight Loss and Exercise; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 21 Years to 69 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Worcester, Massachusetts • Hannover, New Hampshire • Burlington, Vermont

Conditions: Healthy Participants
Interventions: Abiraterone acetate, 250 mg (uncoated, current commercial tablet), Abiraterone acetate, 500 mg (coated, reformulated tablet), Abiraterone acetate, 250 mg (coated, reformulated tablet), Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity, Metabolic Syndrome, Dyslipidemia
Interventions: Not listed
Lead sponsor: Interleukin Genetics, Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 824 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
Interventions: Methenamine Hippurate 1 g tablet, Placebo tablet; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Osteopenia, Osteoporosis, Bone Disease
Interventions: RN564; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Coral Gables, Florida • Miami, Florida • South Miami, Florida + 1 more

Conditions: Renal Insufficiency, Chronic
Interventions: ISMN, Vitamin C; Drug · Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Wounds and Injuries
Interventions: RENASYS◊ DYNAFLOW Instillation Therapy; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 54
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: REGN4336, REGN5678; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Louisville, Kentucky + 8 more

Conditions: Heart Failure
Interventions: Loop Diuretics vs. loop + thiazide diuretics; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
Interventions: LY3300054, Ramucirumab, Abemaciclib, Merestinib, LY3321367; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas • San Antonio, Texas

Conditions: Healthy Adults
Interventions: THCv; Dietary Supplement
Lead sponsor: Canopy Growth Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Non-infectious Uveitis
Interventions: AIN457, AIN 457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 20
States / cities: Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Smoking Cessation
Interventions: Telephone Counseling, Self-Help Materials; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2,277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Renal Cell Carcinoma, Kidney Cancer
Interventions: 124-Iodine-cG250 (124I-cG250), CT; Drug · Procedure
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Los Angeles, California • Stanford, California • Tampa, Florida + 10 more

Conditions: Fertility Disorders, Fertility Issues
Interventions: Endometrial Scratch, Sham procedure; Procedure
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Pancreatic Cancer
Interventions: Proton radiation and chemotherapy; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: End-Stage Renal Disease (ESRD)
Interventions: EPN-701 (Oral); Drug
Lead sponsor: Epizon Pharma, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: umbilical cord blood transplantation, Allopurinol, fludarabine phosphate, Cyclophosphamide, Total body irradiation, Treg infusion, Sirolimus; Biological · Drug · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostate Cancer
Interventions: PET-CT imaging subsystem of the RefleXion X1 System Device; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Respiratory Syncytial Virus Infection
Interventions: Presatovir, Presatovir placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 9
States / cities: Chicago, Illinois • Annapolis, Maryland • Detroit, Michigan + 6 more

Search by objective public record fields.

Substance Use in Assault-Injured Young Adults

Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors

A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet

Association of Genes to Resistance to Weight Loss in Obese Patients

Urinary Track Infection Prevention After Urogynecological Surgery

Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.

Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease

Utilizing RENASYS◊ DYNAFLOW Instillation Therapy System for Wound Management in Adults With Acute and Chronic Wounds

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

Comparing Diuretic Strategies in Hospitalized Heart Failure

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants

Safety and Efficacy of AIN457 in Noninfectious Uveitis

Smokers' Quitline for Asian Language Speakers

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Menstrual Phase Endometrial Scratch in IUI Cycles

Proton Therapy for Unresectable Cancer (CA) of Pancreas

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection